|Over a week ago|
Omega Therapeutics provides update on upcoming milestones » 07:1309/1009/10/21
Omega Therapeutics upcoming milestones and key priorities: complete IND-enabling studies for OTX-2002 and successfully file IND application to FDA during the first half of 2022; nominate additional OEC development candidates in the first half of 2022; file a second IND application targeted for second half of 2022; continue to develop the OMEGA Epigenomic Programming platform and investigate additional development programs to expand pipeline; and publish relevant pre-clinical and early clinical data supporting our programs and platform development.
Omega Therapeutics reports Q2 EPS ($3.36), consensus ($1.21) » 07:1209/1009/10/21
"Our recent successful initial public offering reinforces our commitment to bring potentially transformative programmable mRNA therapeutics that target the epigenetic basis of disease to precisely control gene expression to patients across a wide range of diseases. We are thrilled to bring in new investors through our IPO and to have the continued support of our existing stockholders," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. "The funding provides the necessary financial resources to advance our lead Omega Epigenomic Controller candidate, OTX-2002, for the treatment of Hepatocellular Carcinoma through an Investigational New Drug filing and initial clinical readouts, as well as to continue pre-clinical and IND-enabling studies for several additional OEC development candidates."
Fly Intel: Top five analyst initiations » 09:5408/2408/24/21
OMGA, DOLE, PACK, COIN, MXCT
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Omega Therapeutics (OMGA) initiated with a Buy at Jefferies and an Outperform at Wedbush. 2. Dole (DOLE) initiated with a Buy at Goldman Sachs and Deutsche Bank, initiated with an Overweight at Stephens, a Market Perform at BMO Capital and an Underperform at BofA. 3. Ranpak Holdings (PACK) initiated with a Neutral at Goldman Sachs. 4. Coinbase (COIN) initiated with Buy at Needham. 5. MaxCyte (MXCT) initiated with a Buy at Stifel and BTIG, initiated with an Outperform at Cowen, and William Blair and initiated with an Overweight at Stephens. click here.
Wedbush bullish on Omega Therapeutics, initiates with an Outperform » 08:2808/2408/24/21
As previously reported,…
As previously reported, Wedbush analyst Robert Driscoll initiated coverage of Omega Therapeutics with an Outperform rating and $36 price target. The analyst sees potential for significant value creation as Omega's pipeline of development programs progress into the clinic, and as the platform applies learnings to additional high value indications going forward.
Omega Therapeutics initiated with a Buy at Jefferies » 07:3308/2408/24/21
Jefferies analyst Chris…
Jefferies analyst Chris Howerton initiated coverage of Omega Therapeutics with a Buy rating and $30 price target. Omega is an early-stage platform company developing new class medicines termed "epigenetic controllers," and Howerton tells investors in a research note that its lead programs target c-Myc, which if successful could represent a $4B opportunity in Liver/Lung cancers alone.
Omega Therapeutics initiated with an Outperform at Wedbush » 06:5008/2408/24/21
Wedbush analyst Robert…
Wedbush analyst Robert Driscoll initiated coverage of Omega Therapeutics with an Outperform rating and $36 price target.
Omega Therapeutics initiated with a Buy at Jefferies » 06:2808/2408/24/21
Jefferies analyst Chris…
Jefferies analyst Chris Howerton initiated coverage of Omega Therapeutics with a Buy rating and $30 price target.
Omega Therapeutics initiated with an Overweight at Piper Sandler » 05:0408/2408/24/21
Piper Sandler analyst…
Piper Sandler analyst Edward Tenthoff initiated coverage of Omega Therapeutics with an Overweight rating and $30 price target. Omega is pioneering the development of a novel class of mRNA-encoded medicines, targeting specific insulated genomic domains to correct expression of disease-causing genes, Tenthoff tells investors in a research note. The analyst says the company "rationally designs" modular Omega Epigenomic Controllers to precisely control the level and duration of expression of specific genes. He sees "enormous potential for this novel therapeutic modality to treat a broad range of diseases."
Omega Therapeutics initiated with a Neutral at Goldman Sachs » 05:0008/2408/24/21
Goldman Sachs analyst…
Goldman Sachs analyst Salveen Richter initiated coverage of Omega Therapeutics with a Neutral rating and $22 price target. The analyst is positive on Omega's "potentially revolutionary and unique" technology, preclinical data and "de-risked" LNP delivery system, but says its pipeline is early and lacks near-term value driving catalysts.
|Over a month ago|
Opening Day: Sportradar files for IPO after SPAC talks break off » 08:2708/2108/21/21
ARBK, ARBKF, PRCT, SRAD, QNIU, CMSL, SPRK, SCAN, AUTH, BLK, SPG, MS, GS, BCS, BAC, MXCT, RXST, TNYA, RANI, NUVL, ICVX, RSKD, OMGA, IMRX, INAB, HOOD, RLYB, ABVC
In a quiet week for IPOs,…